You are here

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Palo Alto, California, 94304-1290 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject has been taking an NSAID at least 15 of the past 30 days for index knee pain

- Grades 2 or 3 OA as defined by the Kellgren and Lawrence Grading System of the medial
tibiofemoral joint (joint space narrowing in the medial compartment > lateral
compartment as assessed by x-ray) using the Altman Atlas of OA7. This must be
documented with a report from an x-ray of the study joint taken either at screening or
within 1 year prior to screening

- Subject meets American College of Rheumatology (ACR) clinical classification criteria
for osteoarthritis of the knee, defined by the following: Knee pain and at least 3 of
the following: oAge >50 oMorning stiffness oBony tenderness oBony enlargement oNo palpable warmth of synovium.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subject has a documented history of an allergic reaction (hives, rash, etc.) or a
clinically significant intolerance to celecoxib, sulfonamides, aspirin, or opioids
including oxycodone

- Significant pain outside the index knee, including significant hip or back pain that
can not be distinguished from OA pain or that interferes with ability to walk.
(Patients with bilateral knee OA will be allowed into the study. The index knee should
be defined as the more painful knee

- Predominantly patellofemoral knee osteoarthritis in the index knee as assessed by
clinical examination

- Subject who are unable to discontinue all formulations of prior analgesics other than
acetaminophen during the Washout Period of the study, or who are anticipated to be
unable to discontinue rescue medication for 24 hours prior to the respective visits.
(Low dose aspirin may be taken for cardiac prophylaxis

- Excessive signal knee joint laxity indicative of functional ligamentous deficiency

NCT00484718
Pfizer
Terminated
Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
NCT02528188
All Genders
18+
Years
Multiple Sites
Hip Osteoarthritis, Knee Osteoarthritis
NCT02709486
All Genders
18+
Years
Multiple Sites
Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.
Measures Of Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee: A Randomized, Single-Blind Washout, Double-Blind Treatment, Double Dummy Cross-Over Pilot Trial Using Placebo, Oxycodone And Celecoxib (A9011030)
The Purpose of this trial is to evaluate the use of a cross-over trial design in an osteoarthritis population. We will determine the inter- and intra-subject variability in osteoarthritis (OA) endpoints and evaluate if efficacy can be detected by measuring OA endpoints following treatment with 2 different types of analgesics in a crossover study of this design.
Methodology study to evaluate the use of a cross over design and gait analysis. The study was terminated by mutual consent with the study site at a meeting on the 1 April 2009, because of slow recruitment due to a high screen fail rate. The study was not stopped for safety reasons.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Osteoarthritis
  • Drug: celecoxib
    oral, 100 mg bid
  • Drug: Oxycodone
    oral, 20 mg bid
  • Drug: placebo
    oral bid
  • Active Comparator: A
    Intervention: Drug: celecoxib
  • Active Comparator: B
    Intervention: Drug: Oxycodone
  • Placebo Comparator: C
    Intervention: Drug: placebo


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
6
June 2009
June 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject has been taking an NSAID at least 15 of the past 30 days for index knee pain
  • Grades 2 or 3 OA as defined by the Kellgren and Lawrence Grading System of the medial tibiofemoral joint (joint space narrowing in the medial compartment > lateral compartment as assessed by x-ray) using the Altman Atlas of OA7. This must be documented with a report from an x-ray of the study joint taken either at screening or within 1 year prior to screening
  • Subject meets American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of the knee, defined by the following: Knee pain and at least 3 of the following: oAge >50 oMorning stiffness <30 minutes oCrepitus on active motion oBony tenderness oBony enlargement oNo palpable warmth of synovium.

Exclusion Criteria:

  • Subject has a documented history of an allergic reaction (hives, rash, etc.) or a clinically significant intolerance to celecoxib, sulfonamides, aspirin, or opioids including oxycodone
  • Significant pain outside the index knee, including significant hip or back pain that can not be distinguished from OA pain or that interferes with ability to walk. (Patients with bilateral knee OA will be allowed into the study. The index knee should be defined as the more painful knee
  • Predominantly patellofemoral knee osteoarthritis in the index knee as assessed by clinical examination
  • Subject who are unable to discontinue all formulations of prior analgesics other than acetaminophen during the Washout Period of the study, or who are anticipated to be unable to discontinue rescue medication for 24 hours prior to the respective visits. (Low dose aspirin may be taken for cardiac prophylaxis
  • Excessive signal knee joint laxity indicative of functional ligamentous deficiency
Sexes Eligible for Study: All
40 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00484718
A9011030
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now